Eivind Smeland

554 total citations
22 papers, 441 citations indexed

About

Eivind Smeland is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Eivind Smeland has authored 22 papers receiving a total of 441 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Eivind Smeland's work include Sarcoma Diagnosis and Treatment (11 papers), Acute Lymphoblastic Leukemia research (6 papers) and Vascular Tumors and Angiosarcomas (5 papers). Eivind Smeland is often cited by papers focused on Sarcoma Diagnosis and Treatment (11 papers), Acute Lymphoblastic Leukemia research (6 papers) and Vascular Tumors and Angiosarcomas (5 papers). Eivind Smeland collaborates with scholars based in Norway and Singapore. Eivind Smeland's co-authors include Roy M. Bremnes, Lill‐Tove Busund, Thomas K. Kilvær, Sveinung Wergeland Sørbye, Tom Dønnem, Andrej Valkov, Jarle Aarbakke, Khalid A. Alshibli, Khalid Al‐Shibli and John S. Svendsen and has published in prestigious journals such as PLoS ONE, Biochemical Pharmacology and Journal of Translational Medicine.

In The Last Decade

Eivind Smeland

21 papers receiving 432 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eivind Smeland Norway 14 231 195 98 93 56 22 441
Annalisa Savonarola Italy 16 238 1.0× 98 0.5× 238 2.4× 70 0.8× 42 0.8× 20 550
Tomasz Sarosiek Poland 14 313 1.4× 107 0.5× 154 1.6× 193 2.1× 28 0.5× 38 754
Hideki Makino Japan 11 74 0.3× 170 0.9× 96 1.0× 67 0.7× 32 0.6× 33 419
J. Mazurka Canada 10 120 0.5× 85 0.4× 167 1.7× 37 0.4× 68 1.2× 15 488
Akihiro Ohmoto Japan 14 418 1.8× 99 0.5× 158 1.6× 62 0.7× 114 2.0× 75 706
Beate Haugk United Kingdom 15 326 1.4× 139 0.7× 95 1.0× 34 0.4× 48 0.9× 40 590
E Antoine France 7 294 1.3× 160 0.8× 112 1.1× 129 1.4× 53 0.9× 16 461
Paloma Martín-Martorell Spain 11 279 1.2× 190 1.0× 82 0.8× 35 0.4× 37 0.7× 30 426
Dalin Li China 15 296 1.3× 110 0.6× 210 2.1× 211 2.3× 62 1.1× 27 650
Joseph Catlett United States 11 170 0.7× 129 0.7× 151 1.5× 53 0.6× 136 2.4× 15 501

Countries citing papers authored by Eivind Smeland

Since Specialization
Citations

This map shows the geographic impact of Eivind Smeland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eivind Smeland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eivind Smeland more than expected).

Fields of papers citing papers by Eivind Smeland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eivind Smeland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eivind Smeland. The network helps show where Eivind Smeland may publish in the future.

Co-authorship network of co-authors of Eivind Smeland

This figure shows the co-authorship network connecting the top 25 collaborators of Eivind Smeland. A scholar is included among the top collaborators of Eivind Smeland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eivind Smeland. Eivind Smeland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kilvær, Thomas K., Eivind Smeland, Andrej Valkov, et al.. (2014). The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk. BMC Clinical Pathology. 14(1). 5–5. 17 indexed citations
2.
Sørbye, Sveinung Wergeland, Thomas K. Kilvær, Andrej Valkov, et al.. (2013). Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas. BMC Clinical Pathology. 13(1). 9–9. 3 indexed citations
3.
Sørbye, Sveinung Wergeland, Thomas K. Kilvær, Andrej Valkov, et al.. (2012). Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas. BMC Clinical Pathology. 12(1). 7–7. 23 indexed citations
4.
Sørbye, Sveinung Wergeland, Thomas K. Kilvær, Andrej Valkov, et al.. (2012). Prognostic Impact of Jab1, p16, p21, p62, Ki67 and Skp2 in Soft Tissue Sarcomas. PLoS ONE. 7(10). e47068–e47068. 42 indexed citations
5.
Sørbye, Sveinung Wergeland, Thomas K. Kilvær, Andrej Valkov, et al.. (2012). High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator. OncoImmunology. 1(1). 75–77. 22 indexed citations
6.
Sørbye, Sveinung Wergeland, Thomas K. Kilvær, Andrej Valkov, et al.. (2012). Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clinical Pathology. 12(1). 5–5. 28 indexed citations
7.
Smeland, Eivind, Thomas K. Kilvær, Sveinung Wergeland Sørbye, et al.. (2012). Prognostic Impacts of Hypoxic Markers in Soft Tissue Sarcoma. Sarcoma. 2012. 1–10. 20 indexed citations
8.
Valkov, Andrej, Thomas K. Kilvær, Sveinung Wergeland Sørbye, et al.. (2011). The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas. Journal of Translational Medicine. 9(1). 200–200. 19 indexed citations
9.
Kilvær, Thomas K., Andrej Valkov, Sveinung Wergeland Sørbye, et al.. (2011). Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. Journal of Translational Medicine. 9(1). 104–104. 18 indexed citations
10.
Sørbye, Sveinung Wergeland, Thomas K. Kilvær, Tom Dønnem, et al.. (2011). The Prognostic Impact of TGF-β1, Fascin, NF-κB and PKC-ζ Expression in Soft Tissue Sarcomas. PLoS ONE. 6(3). e17507–e17507. 32 indexed citations
11.
Sørbye, Sveinung Wergeland, Thomas K. Kilvær, Tom Dønnem, et al.. (2011). Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas. PLoS ONE. 6(1). e14611–e14611. 80 indexed citations
12.
Kilvær, Thomas K., Andrej Valkov, Sveinung Wergeland Sørbye, et al.. (2010). Profiling of VEGFs and VEGFRs as Prognostic Factors in Soft Tissue Sarcoma: VEGFR-3 Is an Independent Predictor of Poor Prognosis. PLoS ONE. 5(12). e15368–e15368. 29 indexed citations
13.
Kilvær, Thomas K., Andrej Valkov, Sveinung Wergeland Sørbye, et al.. (2010). Platelet-Derived Growth Factors in Non-GIST Soft-Tissue Sarcomas Identify a Subgroup of Patients with Wide Resection Margins and Poor Disease-Specific Survival. Sarcoma. 2010. 1–10. 12 indexed citations
14.
Smeland, Eivind, Ole‐Martin Fuskevåg, John S. Svendsen, et al.. (1996). High-dose 7-hydroxymethotrexate: Acute toxicity and lethality in a rat model. Cancer Chemotherapy and Pharmacology. 37(5). 415–422. 43 indexed citations
15.
Smeland, Eivind, Roy M. Bremnes, Ole‐Martin Fuskevåg, & Jarle Aarbakke. (1995). Perturbation of methotrexate transport by verapamil, vinblastine, taurocholate and bromosulfophthalein in rat hepatocytes.. PubMed. 15(1). 45–50.
16.
Smeland, Eivind, et al.. (1994). Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. Cancer Chemotherapy and Pharmacology. 34(2). 119–124. 18 indexed citations
17.
Smeland, Eivind, et al.. (1994). Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. Cancer Chemotherapy and Pharmacology. 34(2). 119–124. 3 indexed citations
18.
Smeland, Eivind, et al.. (1993). Interactions of vinblastine and vincristine with methotrexate transport in isolated rat hepatocytes. Cancer Chemotherapy and Pharmacology. 32(3). 209–214. 4 indexed citations
19.
Bremnes, Roy M., Eivind Smeland, N E Huseby, T. J. Eide, & Jarle Aarbakke. (1991). Acute Hepatotoxicity after High‐Dose Methotrexate Administration to Rats. Pharmacology & Toxicology. 69(2). 132–139. 13 indexed citations
20.
Bremnes, Roy M., Eivind Smeland, Nils Peder Willassen, Erik Wist, & Jarle Aarbakke. (1991). Inhibition of 7-hydroxymethotrexate formation by amsacrine. Cancer Chemotherapy and Pharmacology. 28(5). 377–383. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annalisa Savonarola Breakdown of academic impact, for papers by Tomasz Sarosiek Breakdown of academic impact, for papers by Hideki Makino Breakdown of academic impact, for papers by J. Mazurka Breakdown of academic impact, for papers by Akihiro Ohmoto Breakdown of academic impact, for papers by Beate Haugk Breakdown of academic impact, for papers by E Antoine Breakdown of academic impact, for papers by Paloma Martín-Martorell Breakdown of academic impact, for papers by Dalin Li Breakdown of academic impact, for papers by Joseph Catlett
Rankless by CCL
2026